NasdaqCM · Biotechnology

Avalo Therapeutics (AVTX)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+122.7%

$44.15 average target

$19.83+0.01 (+0.1%)Latest market snapshot · Yahoo Finance

Market cap$1.06B

Cash$400.3M

Quarterly burn$20.0M

Pipeline assets10

Short float24.5%

Latest coverage

News & Press Releases

External sources

Aug 19, 2026

Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC FilingMT Newswires

Aug 11, 2026

Do Avalo Therapeutics’ (AVTX) Widening Losses But Better EPS Reveal a Turning Point in Strategy?Simply Wall St.

Aug 6, 2026

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business UpdatesGlobeNewswire

Continue with BioPharma ProUnlock 7 more recent stories and press releases.

Unlock Pro

Company profile

About Avalo Therapeutics

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.